Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Secondary cardiovascular disease (CVD) prevention is critical for patients with vascular conditions like coronary artery disease (CAD) and peripheral artery disease (PAD).
• Managing residual ischemic and bleeding risks in CVD patients on antiplatelet therapy presents a significant clinical challenge.
• Atherosclerosis involves common pathophysiological processes targeted by both anticoagulants and antiplatelets.

Purpose of the Study:

• To evaluate the efficacy and safety of combining rivaroxaban with aspirin for secondary prevention in patients with stable CAD and/or symptomatic PAD.
• To assess the impact of this dual therapy on major adverse cardiovascular events (MACE) and major adverse limb events (MALE).

Main Methods:

• The study involved over 27,000 patients in the global COMPASS trial.
• Participants received either rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily, or aspirin alone.
• Outcomes included major adverse cardiovascular events (MACE), major adverse limb events (MALE), and major bleeding events.

Main Results:

• Rivaroxaban plus aspirin significantly reduced the risk of MACE (myocardial infarction, stroke, CV death) in patients with CAD and/or PAD.
• The combination therapy also significantly reduced the risk of MALE in patients with PAD.
• A significant increase in major bleeding events was observed with rivaroxaban plus aspirin, but not intracranial or fatal bleeding.

Conclusions:

• The dual therapy of rivaroxaban plus aspirin demonstrated a significant net clinical benefit for secondary cardiovascular prevention, outweighing the increased bleeding risk.
• This combination therapy is particularly beneficial for high-risk patients with CAD or symptomatic PAD.
• Rivaroxaban plus aspirin represents an important emerging option for preventing atherothrombotic events in specific patient populations.